Relation Expands GSK Collaboration Worth Up To $110M In Upfront And Milestone Payments To Generate Large-Scale Human Cellular Perturbation Datasets For Disease Biology Research
Share
Why It Matters
GSK is paying another company up to $110 million to help create better tools for understanding how diseases work. This shows GSK is investing in new science that might help them make better medicines.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.